Navigation Links
Cold-EEZE(R) Lozenges not Affected by FDA Advisory for Zicam(R) Intra-Nasal Products
Date:6/16/2009

DOYLESTOWN, Pa., June 16 /PRNewswire-FirstCall/ -- The U.S. Food and Drug Administration (FDA) today advised consumers to stop using three intra-nasal products (gels and swabs) marketed over-the-counter as cold remedies under the Zicam(R) brand because the use of these intra-nasal products are associated with the loss of sense of smell (a condition called anosmia).

While these products are manufactured with a zinc ingredient, The Quigley Corporation (Nasdaq: QGLY), www.quigleyco.com, maker of the popular line of Cold-EEZE(R) zinc gluconate lozenges, assures consumers that their oral zinc lozenge products are not involved in this new FDA advisory, and that the Cold-EEZE(R) brand continues to be supported as safe and effective in clinical research. Only intra-nasal products have shown any association with anosmia.

"The introduction of zinc ions orally has not been connected with the loss of smell," says Darrell T. Hulisz, R.Ph., PharmD, clinical pharmacist/researcher and associate clinical professor at Ohio Northern University College of Pharmacy. "The safe and efficacious use of oral zinc gluconate lozenges is well established."

"The FDA has made a determination that the Zicam intra-nasal products have a growing body of evidence suggesting that they may pose a safety risk to consumers who use them," says Albert Piechotta, executive director of communications at The Quigley Corporation. "Cold-EEZE zinc lozenges have been shown to safely reduce the duration and severity of cold symptoms by nearly half in two clinical studies and have no history of causing adverse events related to anosmia in clinical studies or safety studies."

Since their introduction 14 years ago, Cold-EEZE lozenges have had an outstanding record of safety. Customers can be assured that Cold-EEZE lozenges will continue to be available and is not affected by the FDA's decision to request Zicam remove its nasal products from store shelves."

For more information about Cold-EEZE(R), visit www.coldfight360.com.

About The Quigley Corporation

The Quigley Corporation (Nasdaq: QGLY, http://www.Quigleyco.com) is a diversified natural health medical science company. Its Cold Remedy segment is a leading marketer and manufacturer of the COLD-EEZE(R) family of lozenges, gums and sugar free tablets clinically proven to cut the common cold nearly in half. COLD-EEZE customers include leading national wholesalers and distributors, as well as independent and chain food, drug and mass merchandise stores and pharmacies. The Quigley Corporation has several wholly owned subsidiaries; Quigley Manufacturing Inc. consists of two FDA approved facilities to manufacture COLD- EEZE(R) lozenges as well as fulfill other contract manufacturing opportunities. Quigley Pharma Inc. (http://www.QuigleyPharma.com) conducts research in order to develop and commercialize a pipeline of patented botanical and naturally derived potential prescription drugs.

Forward-Looking Statements

Certain statements in this press release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and involve known and unknown risk, uncertainties and other factors that may cause the Company's actual performance or achievements to be materially different from the results, performance or achievements expressed or implied by the forward-looking statement. Factors that impact such forward-looking statements include, among others, changes in worldwide general economic conditions, changes in interest rates, government regulations, and worldwide competition.

    Media Contact:
    Alyson O'Mahoney
    Robin Leedy & Associates
    (914) 241-0086, ext. 13
    or
    Albert Piechotta, Executive Director of Communications
    The Quigley Corporation
    (215) 345-0919, ext. 122

    Investor Relations Contact:
    Carl Hymans
    G.S. Schwartz & Co.
    212-725-4500-ext 304
    carlh@schwartz.com


'/>"/>
SOURCE Quigley Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. New Product Release: CraniYums(R) App-Suppress(TM) Candy-Like Lozenges, with Pinnothin(R) - a Proven Appetite Suppressant.
2. Video: GlaxoSmithKline Consumer Healthcare Offers Free Nicotine Lozenges for All Certified Pilots and Air Traffic Controllers to Help Them Safely Quit Smoking
3. A childs IQ could be affected by maternal epilepsy
4. Sexual function affected by stem cell transplant according to long-term study
5. Patients perceived cancer care unaffected by lower Medicare reimbursements
6. American Academy of Dermatology: New Study Finds Women More Likely Than Men to be Affected by Acne as Adults
7. Aetna Reminds Members Affected by California Wildfires Where to Call for Help
8. AutismCares Offers Support to Families Affected by California Fires
9. UniCare Announces Temporary Pharmacy Guidelines for Customers Affected by the California Wildfires
10. DaVita Emergency Response Efforts Ensure Vital Treatment for More than 700 Kidney Failure Patients in Need of Life-Saving Dialysis Treatments in Areas Affected by Southern California Wildfires
11. American Society for Aesthetic Plastic Surgery and American Society of Plastic Surgeons Offer Patient Advisory for those Affected by Fig LipoDissolve Closures
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... 2016 , ... TherapySites, the leading website and ... Tennessee Counseling Association. This new relationship allows TherapySites to continue to extend ... exclusive benefits and promotional offers. , "TCA is extremely excited about this new ...
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A Forever Recovery, ... Festival and World’s Longest Breakfast Table in Battle Creek, MI, where the rehabilitation facility ... home to some of the world’s leading providers of cereal and other breakfast foods. ...
(Date:6/25/2016)... , ... June 25, 2016 , ... ... policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at ... on several important health care topics including advance care planning, healthcare costs and ...
(Date:6/25/2016)... , ... June 25, 2016 , ... As a lifelong ... Cum Laude and his M.D from the David Geffen School of Medicine at UCLA. ... to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Those who have ... these feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, as ... Michigan, has released tools for healthy coping following a traumatic event. , Trauma sufferers ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Any dentist who has ... of the current process. Many of them do not even ... technical difficulties and high laboratory costs involved. And those who ... it at such a high cost that the majority of ... Dr. Parsa Zadeh , founder of Dental Evolutions ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 Roche ... received 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) ... severe sepsis or septic shock. With this clearance, Roche ... provide a fully integrated solution for sepsis risk assessment ... associated with bacterial infection and PCT levels in blood ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... 52" report to their offering. ... creates a favourable commercial environment for MedImmune to enter. The ... that will serve to drive considerable growth for effective anti-influenza ... to cap sales considerably, but development is still in its ...
Breaking Medicine Technology: